A country can appear highly attractive on a regional heat map yet prove unsuitable once protocol requirements meet local clinical practice. That is why clinical trial feasibility in Asia cannot be reduced to patient population figures, investigator questionnaires or a comparison of start-up timelines. Sponsors need evidence that a study can recruit the right patients, activate the right sites and generate inspection-ready data within a realistic operating model.
Asia Pacific offers exceptional opportunities for global development programmes: large and diverse patient populations, sophisticated research centres, experienced investigators and access to therapeutic areas with unmet need. It is also a collection of distinct regulatory systems, healthcare pathways, languages, reimbursement models and site capabilities. Strong feasibility converts that complexity into a defensible country and site strategy before costly assumptions become execution risks.
Why Clinical Trial Feasibility in Asia Needs Local Evidence
Regional planning is useful, but trials are activated and enrolled country by country, site by site. A recruitment estimate for South Korea has little value if the selected hospitals already have competing studies in the same indication. A favourable regulatory pathway in Singapore does not answer whether a decentralised model is practical for patients in Indonesia. Equally, a large addressable population in India may not translate into eligible participants when diagnostic practices, treatment patterns and protocol-specific exclusion criteria are considered.
Feasibility should therefore test the operational reality of the protocol. It should establish where patients are diagnosed, how they move through the health system, which specialists control referral pathways, and whether potential participants can complete the required visits, procedures and follow-up. For rare diseases, this often means looking beyond headline prevalence towards centres of excellence, disease registries, advocacy networks and the referral relationships that determine access to patients.
The same discipline applies to competitive intelligence. The relevant question is not simply whether competing trials exist. Sponsors need to understand their enrolment status, eligibility overlap, visit burden, investigational product requirements, use of placebo or standard of care, and the investigators involved. A site may have an excellent record in a therapeutic area but limited capacity to open another study during the proposed recruitment window.
Start With the Protocol, Not the Country List
A credible feasibility programme begins by challenging the protocol through an Asia-Pacific lens. Global eligibility criteria may inadvertently exclude the patients routinely seen in target markets. Required imaging, laboratory assays or specialist procedures may be available only in major metropolitan hospitals. Visit schedules can create avoidable burden for patients travelling long distances, while prohibited concomitant medicines may conflict with established local treatment practice.
This is not an argument for compromising scientific objectives. It is a way to identify where protocol design and regional execution need to meet. Early input from local medical, regulatory and operational specialists can clarify whether amendments, country-specific operational plans or alternative site profiles are needed before the study is committed to a start-up path.
For medical device studies, the assessment also needs to consider operator experience, device availability, hospital procurement processes, training requirements and the practicalities of importation. A technically appropriate site may still be unsuitable if it cannot accommodate device storage, accountability, procedure scheduling or post-market follow-up requirements.
Assess the Variables That Shape Delivery
High-quality feasibility combines structured data with informed local judgement. Site surveys remain valuable, but they should be validated through direct engagement with investigators, site research teams and relevant healthcare stakeholders. Historic performance can guide selection, provided it is interpreted in context: a site’s past recruitment may reflect a different population, protocol burden or level of sponsor support.
The assessment should bring together several connected variables:
- Patient availability and eligibility, including diagnostic rates, standard-of-care pathways, competing trials and realistic monthly enrolment capacity.
- Investigator and site capability, covering therapeutic expertise, staffing, facilities, source documentation practices, equipment and capacity for concurrent studies.
- Regulatory and start-up requirements, including ethics review processes, local sponsorship, import licences, contracts, insurance and essential document expectations.
- Supply and logistics readiness, particularly for temperature-sensitive products, biological samples, devices, central laboratory services and local depot arrangements.
- Patient-centred delivery options, such as home nursing, remote visits, eConsent, travel support and locally appropriate retention measures.
These elements are interdependent. A country with rapid regulatory review may still have protracted contract negotiations at leading public hospitals. A site with strong recruitment potential may need additional staffing or patient travel support to sustain retention. Feasibility should expose these dependencies early enough for the sponsor to decide whether to invest, redesign or select an alternative route.
Country Selection Is a Portfolio Decision
Selecting countries solely on anticipated recruitment can concentrate risk. A more resilient strategy balances speed, quality, regulatory predictability, data requirements, cost and operational continuity. Established research markets may offer mature infrastructure, experienced sites and consistent data quality, while emerging markets may expand access to treatment-naive or under-represented patient populations. Neither category is inherently better. The appropriate mix depends on the programme’s endpoint profile, target population, supply model and development timeline.
For example, an early-phase study may prioritise specialist units, intensive safety oversight and pharmacokinetic capability. A pivotal study may need a broader network of high-enrolling hospitals and a deliberate plan to manage variability in standard of care. Post-marketing and real-world evidence programmes may place greater weight on routine clinical data availability, long-term follow-up and representative patient access.
Country selection should also account for the role each market will play in the overall submission strategy. Data acceptability, ethnic sensitivity considerations, bridging expectations and local regulatory requirements can affect both the value of participation and the evidence package needed after the study closes. These are strategic issues, not simply start-up considerations.
From Site Lists to Site Commitment
A long list of nominally interested sites does not constitute feasibility. The more meaningful indicator is verified commitment from sites that understand the protocol and can articulate where eligible patients will come from. Investigator enthusiasm matters, but so do the research coordinator’s capacity, pharmacy readiness, diagnostic turnaround times and access to the patient pathway.
Site selection should distinguish between scientific suitability and operational readiness. A renowned principal investigator may be essential for scientific credibility, but a broader recruitment network may be required to protect timelines. In some cases, the strongest model combines leading referral centres with carefully qualified regional hospitals that can access patients earlier in their care journey.
Early site engagement also provides an opportunity to test assumptions about informed consent, patient communications and retention. Cultural expectations around family involvement, travel and treatment decisions vary across Asia Pacific. Patient-facing materials and visit models should be designed with local insight, while maintaining consistent ethical and quality standards across the programme.
Build Feasibility Into an Executable Plan
The purpose of feasibility is decision-quality evidence, not a presentation of optimistic projections. Outputs should clearly define recommended countries and sites, recruitment scenarios, assumptions, risks, mitigations and decision points. Sponsors should be able to see the difference between a base-case forecast and an upside scenario, as well as the operational actions required to achieve each.
A practical plan connects feasibility to start-up, regulatory affairs, clinical supply, data management and safety operations. This avoids a common handover failure: a feasibility recommendation that cannot be implemented because local contracts, import processes, central laboratory pathways or monitoring resources were not considered early enough.
Technology can improve oversight when used for a defined purpose. Feasibility dashboards, site intelligence tools and data-led recruitment tracking can help teams compare assumptions with actual performance and intervene sooner. They do not replace local judgement. The value comes from combining visible data with in-country teams that can interpret what is changing at a hospital, within a therapeutic network or across a regulatory environment.
For multinational programmes, an Asia-Pacific-focused CRO can provide that continuity from assessment through delivery. Expecto Health Science combines regional coordination with in-country knowledge across key markets, helping sponsors turn feasibility findings into accountable study start-up and site management plans.
The strongest feasibility work does more than identify where a trial could run. It gives sponsor teams the confidence to make early choices that protect recruitment, patient experience, quality and timelines when the study moves from plan to practice.
